Professor Dingwei Ye: A “Precision Breakthrough” in Prostate Cancer Prevention and Treatment in China | 2025 Pujiang Prostate Cancer Congress

Professor Dingwei Ye: A “Precision Breakthrough” in Prostate Cancer Prevention and Treatment in China | 2025 Pujiang Prostate Cancer Congress

2025.07.21
As the tides of the Pujiang River surge forward, so too does China's momentum in prostate cancer innovation. The 2025 Pujiang Prostate Cancer Academic Congress—held jointly with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC)—took place in Shanghai from June 27–28. The event gathered leading experts from China and abroad to exchange the latest advances and clinical practices in prostate cancer. In an exclusive interview with Oncology Frontier – Urology Frontier, Congress Chair and Professor Dingwei Ye of Fudan University Shanghai Cancer Center shared his perspectives on the current status and future of prostate cancer care in China, along with recent innovations in surgical treatment.
2025 BOC/BOA Kicks Off on July 4! Professor Jun Ma Invites You to Explore Global Frontiers in Hematologic Malignancies and Witness a New Era of Chinese Innovation

2025 BOC/BOA Kicks Off on July 4! Professor Jun Ma Invites You to Explore Global Frontiers in Hematologic Malignancies and Witness a New Era of Chinese Innovation

2025.07.16
The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC), held in conjunction with Best of ASCO 2025 China (BOC/BOA), will take place from July 4–5 in the historic city of Nanjing. This prestigious event will gather leading oncology experts from across China and around the world to reflect on major clinical oncology advances in China over the past year and to present key takeaways from the recently concluded American Society of Clinical Oncology (ASCO) Annual Meeting.
Wenbin Qian: Latest Advances in CAR-NK Cell Therapy for Lymphoma | 2025 Hematology Translational and Innovation Conference

Wenbin Qian: Latest Advances in CAR-NK Cell Therapy for Lymphoma | 2025 Hematology Translational and Innovation Conference

2025.07.16
As summer bloomed in Shanghai and the tide of the Huangpu River caught the morning light, the 2025 Hematology Translational and Innovation Conference, held in parallel with the 10th Shanghai Lymphoid Disease Symposium, took place from June 27 to 29. This major academic event welcomed prominent experts from China and abroad to share cutting-edge achievements, promote the integration of basic science and clinical application in hematology, and foster broad exchanges around emerging therapies, professional training, and science communication.
CAH 2025 | Professor Lei Fan: Advancing a Paradigm Shift in the Treatment of Indolent Lymphoma and Exploring a China-Specific Model for Lifelong Disease Management

CAH 2025 | Professor Lei Fan: Advancing a Paradigm Shift in the Treatment of Indolent Lymphoma and Exploring a China-Specific Model for Lifelong Disease Management

2025.07.16
In early summer, the historic city of Xi’an welcomed a gathering of leading experts at the 19th Annual Meeting of the Chinese Association of Hematologists and the 2025 China Annual Hematology Conference (CAH 2025), held from June 20 to 22. The event was co-hosted by the Chinese Medical Doctor Association and its Hematology Branch, in collaboration with the National Clinical Research Center for Hematologic Diseases – Peking University Institute of Hematology, and the First Affiliated Hospital of Xi’an Jiaotong University.
Prof. Yao Zhu: A “Prevention-Treatment-Research” Integrated Approach to Prostate Cancer Management | 2025 Pujiang Prostate Cancer Conference

Prof. Yao Zhu: A “Prevention-Treatment-Research” Integrated Approach to Prostate Cancer Management | 2025 Pujiang Prostate Cancer Conference

2025.07.14
The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology (CACA-GO) Prostate Cancer Conference, and the Chinese Prostate Cancer Consortium (CPCC) Annual Meeting. Themed “Global Wisdom · Chinese Practice · Precise Breakthroughs,” the event brought together domestic and international experts to exchange the latest advances and practical experience in prostate cancer.
Professor Xudong Yao: The “Shanghai Tenth Hospital Experience” in Prostate Cancer Diagnosis, Treatment, and Research2025 Pujiang Prostate Cancer Conference

Professor Xudong Yao: The “Shanghai Tenth Hospital Experience” in Prostate Cancer Diagnosis, Treatment, and Research2025 Pujiang Prostate Cancer Conference

2025.07.14
The “2025 Pujiang Prostate Cancer Academic Conference,” held in Shanghai from June 27 to 28, was jointly hosted alongside the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Subcommittee of the Chinese Anti-Cancer Association (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC). With the theme “Global Wisdom, Chinese Practice, and Precision Breakthroughs,” the event gathered leading domestic and international experts to share the latest advances and clinical insights in prostate cancer care. At the conference, Professor Xudong Yao, Director of the Department of Urology at Shanghai Tenth People’s Hospital (Tongji University Affiliated Tenth People’s Hospital), delivered a keynote presentation titled “Exploration and Outlook on the Comprehensive Management of Prostate Cancer.” In an interview with Oncology Frontier – UroStream, he discussed his team’s experience and scientific work in prostate cancer management.